For best viewing of the website please use Mozilla Firefox or Google Chrome.
Citation: Zhiwei Wu, Qingliang Li, Yan Liu, Huakun Lv, Zhaojun Mo, Fangjun Li, Qingchuan Yu, Fei Jin, Wei Chen, Yong Zhang, Teng Huang, Xiaosong Hu, Wei Xia, Jiamei Gao, Haisong Zhou, Xuan Bai, Yueyue Liu, Zhenzhen Liang, Zhijun Jiang, Yingping Chen, Jiuwei Zhang, Jialiang Du, Biao Yang, Bo Xing, Yantao Xing, Ben Dong, Qinghai Yang, Chen Shi, Tingdong Yan, Bo Ruan, Haiyun Shi, Xingliang Fan, Dongyang Feng, Weigang Lv, Dong Zhang, Xiangchu Kong, Liuyifan Zhou, Dinghong Que, Hong Chen, Zhongbing Chen, Xiang Guo, Weiwei Zhou, Cong Wu, Qingrong Zhou, Yuqing Liu, Jian Qiao, Ying Wang, Xinguo Li, Kai Duan, Yuliang Zhao, Gelin Xu, Xiaoming Yang. Efficacy, safety and immunogenicity of hexavalent rotavirus vaccine in Chinese infants [J].VIROLOGICA SINICA, 2022, 37(5) : 724-730.  http://dx.doi.org/10.1016/j.virs.2022.07.011

Efficacy, safety and immunogenicity of hexavalent rotavirus vaccine in Chinese infants

  • A randomized, double-blind, placebo-controlled multicenter trial was conducted in healthy Chinese infants to assess the efficacy and safety of a hexavalent live human-bovine reassortant rotavirus vaccine (HRV) against rotavirus gastroenteritis (RVGE). A total of 6400 participants aged 6–12 weeks were enrolled and randomly assigned to either HRV (n = 3200) or placebo (n = 3200) group. All the subjects received three oral doses of vaccine four weeks apart. The vaccine efficacy (VE) against RVGE caused by rotavirus serotypes contained in HRV was evaluated from 14 days after three doses of administration up until the end of the second rotavirus season. VE against severe RVGE, VE against RVGE hospitalization caused by serotypes contained in HRV, and VE against RVGE, severe RVGE, and RVGE hospitalization caused by natural infection of any serotype of rotavirus were also investigated. All adverse events (AEs) were collected for 30 days after each dose. Serious AEs (SAEs) and intussusception cases were collected during the entire study. Our data showed that VE against RVGE caused by serotypes contained in HRV was 69.21% (95%CI: 53.31–79.69). VE against severe RVGE and RVGE hospitalization caused by serotypes contained in HRV were 91.36% (95%CI: 78.45–96.53) and 89.21% (95%CI: 64.51–96.72) respectively. VE against RVGE, severe RVGE, and RVGE hospitalization caused by natural infection of any serotype of rotavirus were 62.88% (95%CI: 49.11–72.92), 85.51% (95%CI: 72.74–92.30) and 83.68% (95%CI: 61.34–93.11). Incidences of AEs from the first dose to one month post the third dose in HRV and placebo groups were comparable. There was no significant difference in incidences of SAEs in HRV and placebo groups. This study shows that this hexavalent reassortant rotavirus vaccine is an effective, well-tolerated, and safe vaccine for Chinese infants.

  • 加载中
    1. Chan, I.S.F., Bohidar, N.R., 1998. Exact power and sample size for vaccine efficacy studies. Commu. Stat-Theory Methods 27, 1305-1322.

    2. Chen, D., Liu, C., Lv, H., Shi, H., Shang, J., Yin, Y., Luo, P., Luo, W., 2019. Investigation on rotavirus diarrhea in infants aged two years and below in Yuhan. Prev. Med. 31, 628-630 (In Chinese).

    3. Chen, H., Li, Q., Duan, K., Shi, C., Zhang, D., Dong, B., Bai, X., Qiao, J., Xu, G., Yang, X., Gao, Z., Li, F., Lv, H., Zhou, H., Yan, T., Shi, H., 2021. Molecular epidemiological characteristics of rotavirus VP7 gene in zhengding county of Hebei province, xiangtan county of hunan province and yuhuan city of Zhejiang province, China from 2016 to 2017. Chin J Biologicals 34, 415-427 (In Chinese).

    4. Ciarlet, M., Schodel, F., 2009. Development of a rotavirus vaccine:clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine. RotaTeq. Vaccine 27 (Suppl. 6), G72-G81.

    5. Clements-Mann, M.L., Dudas, R., Hoshino, Y., Nehring, P., Sperber, E., Wagner, M., Stephens, I., Karron, R., Deforest, A., Kapikian, A.Z., 2001. Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants. Vaccine 19, 4676-4684.

    6. De Vos, B., Han, H.H., Bouckenooghe, A., Debrus, S., Gillard, P., Ward, R., Cheuvart, B., 2009. Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes:integrated analysis of randomized controlled trials. Pediatr. Infect. Dis. J. 28, 261-266.

    7. Dhingra, M.S., Kundu, R., Gupta, M., Kanungo, S., Ganguly, N., Singh, M.P., Bhattacharya, M.K., Ghosh, R., Kumar, R., Sur, D., Chadha, S.M., Saluja, T., 2014.Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1-G4)Bovine-Human Reassortant Rotavirus vaccine (BRV-TV) in healthy Indian adults and infants. Vaccine 32 (Suppl. 1), A117-A123.

    8. Fang, Z.Y., Wang, B., Kilgore, P.E., Bresee, J.S., Zhang, L.J., 2005. Sentinel hospital surveillance for rotavirus diarrhea in the People's Republic of China, August 2001-July 2003. J Infect Dis 192 (S), S94-S99.

    9. Kulkarni, P.S., Desai, S., Tewari, T., Kawade, A., Goyal, N., Garg, B.S., Kumar, D., Kanungo, S., Kamat, V., Kang, G., Bavdekar, A., Babji, S., Juvekar, S., Manna, B., Dutta, S., Angurana, R., Dewan, D., Dharmadhikari, A., Zade, J.K., Dhere, R.M., Fix, A., Power, M., Uprety, V., Parulekar, V., Cho, I., Chandola, T.R., Kedia, V.K., Raut, A., Flores, J., 2017. A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants. Vaccine 35, 6228-6237.

    10. Lau, Y.L., Nelson, E.A., Poon, K.H., Chan, P.K., Chiu, S., Sung, R., Leung, C.W., Ng, D., Ma, Y.M., Chan, D., Lee, T.L., Tang, J., Kwan, Y.W., Ip, P., Ho, M., Fung, L.W., Tang, H., Suryakiran, P.V., Han, H.H., Bock, H., Hong Kong Rotarix Study, G., 2013.Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age:a randomized, controlled trial. Vaccine 31, 2253-2259.

    11. Li, R.C., Huang, T., Li, Y., Luo, D., Tao, J., Fu, B., Si, G., Nong, Y., Mo, Z., Liao, X., Luan, I., Tang, H., Rathi, N., Karkada, N., Han, H.H., 2014. Human rotavirus vaccine(RIX4414) efficacy in the first two years of life:a randomized, placebo-controlled trial in China. Hum. Vaccines Immunother. 10, 11-18.

    12. Liu, N., Xu, Z., Li, D., Zhang, Q., Wang, H., Duan, Z.J., 2014. Update on the disease burden and circulating strains of rotavirus in China:a systematic review and meta-analysis.Vaccine 32, 4369-4375.

    13. Liu, Y., Li, Q., Bai, X., Jiang, Z., Zhang, J., Feng, D., Yang, B., Dong, B., Chen, T., Yan, T., He, S., Yang, Kejia, Li, F., Mo, Z., Wang, X., Xu, G., 2020. Epidemiological investigation on rotavirus diarrhea in infants at ages of less than 2 years in xiangtan county, hunan province and Rongshui county, Guangxi zhaung autonomous region, China. Chin. J. Biologicals. 33, 684-688 (In Chinese).

    14. Mo, Z., Mo, Y., Li, M., Tao, J., Yang, X., Kong, J., Wei, D., Fu, B., Liao, X., Chu, J., Qiu, Y., Hille, D.A., Nelson, M., Kaplan, S.S., 2017. Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants:a randomized, double-blind, placebo-controlled trial. Vaccine 35, 5897-5904.

    15. National Medical Products Administration (NMPA), 2005. Guidelines for grading criteria of adverse events in clinical trials of preventive vaccines. (Registration No. 493).https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20051014010101369.html.

    16. National Medical Products Administration (NMPA), 2019. Guidelines for grading criteria of adverse events in clinical trials of preventive vaccines. (Registration No.102). http s://www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20191231111901460.html.

    17. Phua, K.B., Lim, F.S., Lau, Y.L., Nelson, E.A., Huang, L.M., Quak, S.H., Lee, B.W., Van Doorn, L.J., Teoh, Y.L., Tang, H., Suryakiran, P.V., Smolenov, I.V., Bock, H.L., Han, H.H., 2012. Rotavirus vaccine RIX4414 efficacy sustained during the third year of life:a randomized clinical trial in an Asian population. Vaccine 30, 4552-4557.

    18. Vesikari, T., Karvonen, A.V., Majuri, J., Zeng, S.Q., Pang, X.L., Kohberger, R., Forrest, B.D., Hoshino, Y., Chanock, R.M., Kapikian, A.Z., 2006. Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children. J. Infect. Dis. 194, 370-376.

    19. Wang, S.J., Chen, L.N., Wang, S.M., Zhou, H.L., Qiu, C., Jiang, B., Qiu, T.Y., Chen, S.L., von Seidlein, L., Wang, X.Y., 2022. Genetic characterization of two G8P[8] rotavirus strains isolated in Guangzhou, China, in 2020/21:evidence of genome reassortment.BMC Infect. Dis. 22, 579.

    20. Wang, L.P., Zhou, S.X., Wang, X., Lu, Q.B., Shi, L.S., Ren, X., Zhang, H.Y., Wang, Y.F., Lin, S.H., Zhang, C.H., Geng, M.J., Zhang, X.A., Li, J., Zhao, S.W., Yi, Z.G., Chen, X., Yang, Z.S., Meng, L., Wang, X.H., Liu, Y.L., Cui, A.L., Lai, S.J., Liu, M.Y., Zhu, Y.L., Xu, W.B., Chen, Y., Wu, J.G., Yuan, Z.H., Li, M.F., Huang, L.Y., Li, Z.J., Liu, W., Fang, L.Q., Jing, H.Q., Hay, S.I., Gao, G.F., Yang, W.Z., Chinese Centers for Disease Control and Prevention (CDC) Etiology of Diarrhea Surveillance Study Team, 2021.Etiological, epidemiological, and clinical features of acute diarrhea in China. Nat.Commun. 12, 2464.

    21. Wang, X.Y., Riewpaiboon, A., von Seidlein, L., Chen, X.B., Kilgore, P.E., Ma, J.C., Qi, S.X., Zhang, Z.Y., Hao, Z.Y., Chen, J.C., Xu, Z.Y., 2009. Potential cost effectiveness of a rotavirus immunization program in rural China. Clin. Infect. Dis. 49, 1202-1210.

    22. World Health Organization (WHO), 2007. Guidelines to assure the quality, safety and efficacy of live attenuated rotavirus vaccines (oral), Annex 3, TRS No 941. https://www.who.int/publications/m/item/oral-live-attenuated-rotavirus-vaccines-anne x-3-trs-no-941.

    23. Wu, Z.W., Li, Q.L., Zhou, H.S., Duan, K., Gao, Z., Zhang, X.J., Jiang, Z.J., Hao, Z.Y., Jin, F., Bai, X., Li, Q., Xu, G.L., Zhao, Y.L., Yang, X.M., 2021. Safety and immunogenicity of a novel oral hexavalent rotavirus vaccine:a phase I clinical trial. Hum. Vaccines Immunother. 17, 2311-2318.

    24. Zhang, J., Zhang, Y., Gao, Z., Liu, Y., Li, Q., Wu, Z., Su, T., Yang, Z., Zhao, Y., 2020. Monitoring results of rotavirus diarrhea in infants aged 0-24 months in a county of Hebei Province. Pract. Prev. Med. 27, 708-711.

    25. Zhang, T., Li, J., Jiang, Y.Z., Xu, J.Q., Guan, X.H., Wang, L.Q., Chen, J., Liang, Y., 2022. Genotype distribution and evolutionary analysis of rotavirus associated with acute diarrhea outpatients in Hubei, China, 2013-2016. Virol. Sin. 37, 503-512.

  • 加载中

Article Metrics

Article views(356) PDF downloads(8) Cited by()

Related
Proportional views
    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Efficacy, safety and immunogenicity of hexavalent rotavirus vaccine in Chinese infants

      Corresponding author: Yuliang Zhao, yuliang_zh@163.com
      Corresponding author: Gelin Xu, gelinxu@qq.com
      Corresponding author: Xiaoming Yang, yangxiaoming@sinopharm.com
    • a Hebei Center for Disease Control and Prevention, Shijiazhuang, 050021, China;
    • b National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China;
    • c National Institutes for Food and Drug Control, Beijing, 100050, China;
    • d Zhejiang Center for Disease Control and Prevention, Hangzhou, 310051, China;
    • e Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, 530028, China;
    • f Hunan Center for Disease Control and Prevention, Changsha, 410005, China;
    • g Zhengding County Center for Disease Control and Prevention, Shijiazhuang, 050800, China;
    • h Daming County Center for Disease Control and Prevention, Handan, 056900, China;
    • i Liucheng County Center for Disease Control and Prevention, Liuzhou, 545200, China;
    • j Xiangtan County Center for Disease Control and Prevention, Xiangtan, 411228, China;
    • k Yuhuan County Center for Disease Control and Prevention, Taizhou, 317600, China;
    • l Yongnian County Center for Disease Control and Prevention, Handan, 056000, China;
    • m Rongshui Miao Autonomous County Center for Disease Control and Prevention, Liuzhou, 545300, China;
    • n You County Center for Disease Control and Prevention, Zhuzhou, 412315, China;
    • o Longyou County Center for Disease Control and Prevention, Quzhou, 324400, China;
    • p Laishui County Center for Disease Control and Prevention, Baoding 074100, China;
    • q Jiangshan County Center for Disease Control and Prevention, Quzhou, 324100, China;
    • r China National Biotec Group Company Limited, National Engineering Technology Research Center for Combined Vaccines, Wuhan, 430207, China

    Abstract: A randomized, double-blind, placebo-controlled multicenter trial was conducted in healthy Chinese infants to assess the efficacy and safety of a hexavalent live human-bovine reassortant rotavirus vaccine (HRV) against rotavirus gastroenteritis (RVGE). A total of 6400 participants aged 6–12 weeks were enrolled and randomly assigned to either HRV (n = 3200) or placebo (n = 3200) group. All the subjects received three oral doses of vaccine four weeks apart. The vaccine efficacy (VE) against RVGE caused by rotavirus serotypes contained in HRV was evaluated from 14 days after three doses of administration up until the end of the second rotavirus season. VE against severe RVGE, VE against RVGE hospitalization caused by serotypes contained in HRV, and VE against RVGE, severe RVGE, and RVGE hospitalization caused by natural infection of any serotype of rotavirus were also investigated. All adverse events (AEs) were collected for 30 days after each dose. Serious AEs (SAEs) and intussusception cases were collected during the entire study. Our data showed that VE against RVGE caused by serotypes contained in HRV was 69.21% (95%CI: 53.31–79.69). VE against severe RVGE and RVGE hospitalization caused by serotypes contained in HRV were 91.36% (95%CI: 78.45–96.53) and 89.21% (95%CI: 64.51–96.72) respectively. VE against RVGE, severe RVGE, and RVGE hospitalization caused by natural infection of any serotype of rotavirus were 62.88% (95%CI: 49.11–72.92), 85.51% (95%CI: 72.74–92.30) and 83.68% (95%CI: 61.34–93.11). Incidences of AEs from the first dose to one month post the third dose in HRV and placebo groups were comparable. There was no significant difference in incidences of SAEs in HRV and placebo groups. This study shows that this hexavalent reassortant rotavirus vaccine is an effective, well-tolerated, and safe vaccine for Chinese infants.

    Reference (25) Relative (20)

    目录

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return